mmp9 (Cell Signaling Technology Inc)
Structured Review

Mmp9, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mmp9/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "circ_0103896/miR-432–5p/FTO feedback loop suppresses the formation and progression of intracranial aneurysm"
Article Title: circ_0103896/miR-432–5p/FTO feedback loop suppresses the formation and progression of intracranial aneurysm
Journal: Non-coding RNA Research
doi: 10.1016/j.ncrna.2025.11.001
Figure Legend Snippet: Downregulation of circ_0103896 is associated with the phenotypic switch of hBVSMCs from a contractile to a synthetic state. ( A ) Expression of circ_0103896 in hBVSMCs following stimulation with PDGF-BB (10 ng/mL) for the indicated times, determined by RT-qPCR. ( B ) hBVSMCs were transfected with siRNA or overexpression plasmids targeting circ_0103896, or corresponding controls, and circ_0103896 expression was quantified by RT-qPCR. ∗∗ P < 0.01 and ∗∗∗ P < 0.001. ( C-E ) Representative bar graphs ( C, E ) and immunoblots ( D ) showing expression of α-SMA and SM22α at the transcriptional ( C ) and translational ( D, E ) levels, assessed by RT-qPCR ( C ) and western blotting ( D, E ), respectively, in differentially treated hBVSMCs. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001. ( F-I ) Bar graphs showing the expression of inflammatory cytokines TNF-α ( F ), IL1B ( G ), IL6 ( H ), and iNOS ( I ), in differentially treated hBVSMCs. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001. ( J, K ) Representative immunoblots ( J ) and quantification ( K ) showing MMP2 and MMP9 protein levels in differentially treated hBVSMCs. ( L ) Cell proliferation of hBVSMCs under the indicated conditions was assessed using the MTT assay. ∗∗ P < 0.01 and ∗∗∗ P < 0.001. ( M, N ) Representative images ( M ) and quantification ( N ) showing migration of hBVSMCs with or without circ_0103896 silencing or overexpression following PDGF-BB treatment. ∗∗∗∗ P < 0.0001. ( O, P ) Representative histograms ( O ) and quantification ( P ) showing apoptosis of hBVSMCs with or without circ_0103896 silencing or overexpression following PDGF-BB treatment. ∗∗ P < 0.01. Data are presented as mean ± SEM from ≥3 independent biological replicates (separate hBVSMCs cultures). Technical replicates (triplicate wells/qPCR reactions) were averaged within each experiment. Comparisons between two groups were analyzed using an unpaired Student's t -test; multiple-group comparisons were analyzed by one-way ANOVA followed by Tukey's post hoc test. ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001; ∗∗∗∗ P < 0.0001.
Techniques Used: Expressing, Quantitative RT-PCR, Transfection, Over Expression, Western Blot, MTT Assay, Migration
Figure Legend Snippet: circ_0103896 expression is negatively correlated with IA severity in mice. ( A ) Representative H&E-stained images showing vessel wall integrity in IA mice subjected to different treatments. ( B ) Quantification of IA severity based on aneurysmal scores in mice indicated treatments. ∗∗ P < 0.01 and ∗∗∗∗ P < 0.0001. ( C ) Grade distribution of aneurysms in IA mice with differential treatments, displayed as pie charts. ( D-G ) Expression levels of inflammatory mediators, including TNF-α ( D ), IL1B ( E ), MMP9 ( F ), and MMP2 ( G ), in cerebral arteries of IA mice under the indicated treatments. ∗∗ P < 0.01 and ∗∗∗ P < 0.001. In vivo data are represented as mean ± SEM, with each mouse representing one biological replicate ( n = 6 per group unless otherwise indicated). Aneurysmal scores were analyzed using one-way ANOVA followed by Tukey's post hoc test; The IA grade distributions were analyzed using the chi-square test. ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001. Mice were randomly allocated to groups using a computer-generated sequence stratified by baseline body weight. Histological scoring and grade assignment were performed on coded samples by two independent investigators blinded to treatment groups. Sample sizes ( n = 6 per group) were determined a priori based on a power analysis for the aneurysmal score (α = 0.05, power = 0.8, expected mean difference = 1.3, SD = 0.8).
Techniques Used: Expressing, Staining, In Vivo, Generated, Sequencing
Figure Legend Snippet: Suppression of circ_0103896 promotes the phenotypic switch of hBVSMCs from a contractile to a synthetic state via miR-432-5p. hBVSMCs were transfected with control vector (p-NC), circ_0103896 overexpression vector (p-Circ), p-Circ and miR-432–5p mimic (p-Circ + mimic), siRNA negative control (si-NC), siRNA against circ_0103896 (si-Circ), and siRNA against circ_0103896 combined with anti-miR-432–5p (si-Circ + Anti-miR). Following transfection, cells were treated with PDGF-BB for 24 h. ( A ) RT-qPCR analysis of miR-432-50 expression after differential transfection. ∗∗∗ P < 0.001. ( B, C ) Transcriptional levels of α-SMA ( ACTA2 ) ( B ) and SM-22α ( TAGLN ) ( C ) in hBVSMCs after indicated treatments. ∗ P < 0.05 and ∗∗∗ P < 0.001. ( D, E ) Representative western blots ( D ) and quantification ( E ) of α-SMA and SM22α protein expression. ∗ P < 0.05 and ∗∗ P < 0.01. ( F, G ) mRNA expression of inflammation-associated cytokines: TNF-α and IL1B ( F ) and IL6 and iNOS ( G ) in hBVSMCs under indicated treatments measured by RT-qPCR. ∗∗∗ P < 0.001. ( H, I ) Representative western blots ( H ) quantification ( I ) of MMP2 and MMP9 protein levels in hBVSMCs after indicated treatments. ∗∗ P < 0.01 and ∗∗∗ P < 0.001. ( J ) Cell proliferation determined with or without indicated transfection under PDGF-BB treatment. ∗∗∗ P < 0.001. ( K, L ) Representative images ( K ) and quantification ( L ) of hBVSMC migration. ∗∗∗ P < 0.001. ( M, N ) Flow cytometry analysis of apoptosis in hBVSMCs under differential treatments. ∗∗∗ P < 0.001. Data are presented as mean ± SEM from ≥3 independent biological experiments. Technical replicates (triplicate wells or qPCR reactions) were averaged within each experiment. Statistical significance was assessed using one-way ANOVA with Tukey's post hoc test. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.
Techniques Used: Transfection, Control, Plasmid Preparation, Over Expression, Negative Control, Quantitative RT-PCR, Expressing, Western Blot, Migration, Flow Cytometry
Figure Legend Snippet: FTO is regulated by the circ_0103896/miR-432–5p axis in hBVSMCs. ( A ) Schematic highlighting the predicted binding sites of miR-432–5p within the 3′UTR of FTO. ( B ) Luciferase essay in hBVSMCs comparing WT and mutant FTO 3′UTRs following miR-432–5p mimic transfection. ∗∗∗ P < 0.001. ( C-E ) FTO expression in hBVSMCs after transfection with circ_0103896 overexpression vectors or miR-432–5p mimics, assessed by RT-qPCR ( C ) and Western blot ( D, E ). ∗∗∗ P < 0.001. ( F-I ) Protein expression of α-SMA ( F, G ), SM22α ( F, G ), and MMP2 and MMP9 ( H, I ), in hBVSMCs transfected with circ_0103896 or miR-432–5p mimics. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001. ( J-N ) Assessment of hBVSMC proliferation ( J ), migration ( K, L ), and apoptosis ( M, N ) after transfection with FTO plasmids or miR-432–5p mimics, using MTT assay, Transwell migration, and cell apoptosis analysis. ∗∗ P < 0.01 and ∗∗∗ P < 0.001. Data are represented as mean ± SEM from ≥3 independent biological replicates. qPCR and luciferase assays were performed in technical triplicate. Statistical comparisons were conducted using an unpaired Student's t -test for two-group comparisons or one-way ANOVA with Tukey's post hoc test for multiple groups. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.
Techniques Used: Binding Assay, Luciferase, Mutagenesis, Transfection, Expressing, Over Expression, Quantitative RT-PCR, Western Blot, Migration, MTT Assay
Figure Legend Snippet: FTO mediates m 6 A modification of circ_0103896, establishing a positive feedback loop that reinforces circ_0103896 expression. ( A, B ) Global RNA m 6 A levels in hBVSMCs after FTO overexpression or silencing, measured by MeRIP-qPCR ( A ) and m 6 A dot-blot assay ( B ). Dot-blot signals were normalized to methylene blue staining. ∗∗ P < 0.01. ( C ) MeRIP analysis of circ_0103896 m 6 A modification in hBVSMCs following FTO overexpression or silencing. ∗∗ P < 0.01. ( D ) RT-qPCR measurement of circ_0103896 expression in hBVSMCs after FTO overexpression or silencing. ∗ P < 0.05 and ∗∗∗ P < 0.001. ( E ) RIP analysis showing binding between FTO and circ_0103896 in hBVSMCs. ∗∗∗ P < 0.001. ( F, G ) Representative western blots ( F ) and quantification ( G ) blots of α-SMA and SM22α protein levels after indicated transfections. ∗∗∗ P < 0.001. ( H, I ) Representative western blots ( H ) and quantification ( I ) of MMP2 and MMP9 protein levels in hBVSMCs after indicated transfections. ∗∗∗ P < 0.001. ( J ) MTT assay assessing hBVSMC proliferation following circ_0103896 silencing, FTO overexpression, or combined treatments. ∗∗ P < 0.01 and ∗∗∗ P < 0.001. ( K, L ) Representative images ( K ) and quantification ( L ) of hBVSMC migration after circ_0103896 silencing, FTO overexpression, or combined treatments. ∗∗∗ P < 0.001. ( M, N ) Representative histograms ( M ) and quantification ( N ) of apoptosis in hBVSMCs after circ_0103896 silencing, FTO overexpression, or combined treatments. ∗∗ P < 0.01 and ∗∗∗ P < 0.001. Data are presented as mean ± SEM from ≥3 independent biological replicates. MeRIP and dot-blot assays were performed in technical triplicate for each sample. Comparisons were analyzed using one-way ANOVA with Tukey's post hoc test. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.
Techniques Used: Modification, Expressing, Over Expression, Dot Blot, Staining, Quantitative RT-PCR, Binding Assay, Western Blot, Transfection, MTT Assay, Migration
Figure Legend Snippet: circ_0103896 suppresses IA formation and progression in vivo via the circ_0103896/miR-432–5p/FTO feedback loop. ( A ) Representative H&E-stained images illustrating vessel wall integrity in IA mice under different treatments. ( B ) Representative bar graph depicting the aneurysmal scores of IA mice under differential treatments. ∗∗ P < 0.01 and ∗∗∗∗ P < 0.0001. ( C ) Pie charts depicting the distribution of IA grades across treatment groups. ( D-G ) Representative bar graphs showing mRNA expression of inflammatory mediators, TNF-α ( D ), IL1B ( E ), MMP9 ( F ), and MMP2 ( G ), in cerebral arteries of differentially treated IA mice. ∗∗∗ P < 0.001. Each mouse represents one biological replicate ( n = 6 per group unless otherwise indicated). Data are presented as mean ± SEM. Aneurysmal scores and cytokine expression were compared using one-way ANOVA with Tukey's post hoc test; The IA grade distributions were analyzed by chi-square test. ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001. Mice were randomly assigned to groups using a computer-generated sequence stratified by baseline body weight. Histological scoring, grade assignment, and cytokine quantification were performed on coded samples by investigators blinded to group allocation. Group sizes ( n = 6 per group) were determined a priori based on power calculation for the aneurysmal score (α = 0.05, power = 0.8, expected mean difference = 1.3, SD = 0.8).
Techniques Used: In Vivo, Staining, Expressing, Generated, Sequencing

